<DOC>
	<DOCNO>NCT01921309</DOCNO>
	<brief_summary>To demonstrate safety effectiveness Trinity™ BIOLOX delta™ Ceramic-on-Ceramic Total Hip System comparison Trinity™ Acetabular Hip System , FDA clear use U.S . The comparison base upon clinical success Month 24 endpoint .</brief_summary>
	<brief_title>Trinity™ BIOLOX Delta™ CoC THR Multi-center Study</brief_title>
	<detailed_description>The clinical research result Trinity™ BIOLOX delta™ Ceramic-on-Ceramic Total Hip System compare control device Clinical success base upon Harris Hip Scores evaluate functional status , adverse event , radiological assessment device failure ( defined removal , replacement , modification device component ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>1. preoperative Harris Hip Score ≤ 70 . 2. preoperative Harris Hip Total Pain score least moderate . 3. diagnosed noninflammatory degenerative joint disease include osteoarthritis avascular necrosis , rheumatoid arthritis , correction functional deformity , developmental hip dysplasia ( DDH ) congenital hip dysplasia ( CDH ) . 4. pain rating none slight least 12 month postoperative contralateral hip , applicable . 5. sufficient femoral acetabular bone stock determine clinician , suitable receive implant confirm xrays . 1. nutritional problem ( protein , calorie , vitamin/mineral deficiency ) may impair wound heal mechanism determine clinician /investigator . 2. neurological disorder may interfere adversely affect gait , balance , weight bearing ( e.g . muscular dystrophy , multiple sclerosis ) . 3. diagnosed metabolic disorder ( e.g . osteomalacia ) , may impair bone metabolism . 4. diagnosed systemic disease would affect welfare overall outcome study ( i.e . Paget 's disease , renal osteodystrophy ) 5. immunologically suppress . 6. receive systemic steroid therapy , exclude inhaler , within 3 month prior surgery . 7. diagnose Charcot 's disease , metastatic neoplastic disease . 8. evidence active infection may spread area body ( e.g . osteomyelitis , pyogenic infection hip joint , overt infection , untreated urinary tract infection , etc. ) . 9. presence previous prosthetic hip replacement device ( type , include surface replacement arthroplasty , endoprosthesis , etc . ) hip joint operate . 10. previous Girdlestone procedure ( resection arthroplasty ) surgical fusion hip operate . 11. diagnosed systemic lupus erythematosus , pigment villonodular synovitis , juvenile rheumatoid arthritis diagnose autoimmune etiology . 12. diagnosed osteoporosis evidence DEXA scan male 75 female 65 year age ( within last 12 month ) . 13. require structural bone graft order support prosthetic component ( ) shape bone receive implant ( ) . 14. acute femoral neck fracture hip fracture . 15. knee amputation contralateral and/or ipsilateral leg . 16. exist total hip arthroplasty contralateral hip pain rating 3 scale 0 10 , 0 `` pain '' 10 `` severe pain '' . 17. total hip arthroplasty contralateral hip within past 12 month . 18. previously receive metalonmetal hip arthroplasty . 19. highly communicable disease disease may limit followup ( e.g . immunocompromised condition , hepatitis , active tuberculosis , etc. ) . 20. known sensitivity device material . 21 . Females pregnant . 22 . Patients prisoner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>avascular necrosis</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>correction functional deformity</keyword>
	<keyword>dysplasia hip</keyword>
</DOC>